Background: Oral nicotinamide (form of vitamin B3) mitigates some effects of UV radiation through decreasing ATP depletion and glycolytic blockade.
Randomized, placebo-controlled trial of nicotinamide 500mg BID in patients at high risk (>= 2 nonmelanoma skin cancers in the past 5 years). Incidence of all new NMSCs 23% lower in nicotinamide group compared to placebo at 12 mos. Individual rates of SCC, BCC and AK also lower in nicotinamide group. Effect ended with end of therapy.
Conclusion: this could be a safe, low-side-effect option for skin cancer prevention.
N Engl J Med 2015 Oct 22; 373:1618.